MCP Sign the guestbook
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
 QUICK SEARCH:   [advanced]


     


A more recent version of this article appeared on October 1, 2008.
This Article
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
R800007-MCP200v1
7/10/1824    most recent
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Glossary
Right arrow reprints & permissions
Google Scholar
Right arrow Articles by Edwards, A. V.G.
Right arrow Articles by Cordwell, S. J.
PubMed
Right arrow PubMed Citation
Right arrow Articles by Edwards, A. V.G.
Right arrow Articles by Cordwell, S. J.
Social Bookmarking
 Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

Submitted on May 8, 2008
Revised on July 30, 2008
Accepted on July 30, 2008

The role of proteomics in clinical cardiovascular biomarker discovery

Alistair V.G. Edwards, Melanie Y. White, and Stuart J. Cordwell

School of Molecular and Microbial Biosciences, The University of Sydney, NSW 2006

Corresponding Author: s.cordwell{at}mmb.usyd.edu.au

Cardiovascular disease remains the most common cause of death in the developed world, and is predicted by the World Health Organization to kill approximately 20 million people worldwide each year until at least 2015. In light of these figures, work on producing superior tools for clinical use in the cardiovascular field is intensive. As proteins are the primary effectors of cellular function, a significant majority of this work focuses on the role of proteins in the cardiovascular system in physiological and pathological states in order to outline both mechanisms and markers of disease. One of the most effective ways to investigate these on a global basis is through proteomic analysis, which allows for broad spectrum screening of cellular protein or peptide complements during cardiovascular pathogenesis. Furthermore, specific technologies are now available to screen animal model or human blood samples for novel, improved markers of chronic disease states, such as atherosclerosis, or for earlier indicators of acute myocardial stress, including ischemia / reperfusion injury and heart failure. This review summarises current literature on the key aspects of proteomics and peptidomics related to clinical cardiovascular science.


Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?





HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
 All ASBMB Journals   Journal of Biological Chemistry 
 Journal of Lipid Research   ASBMB Today 
Copyright © 2008 by the American Society for Biochemistry and Molecular Biology.